JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

JAK

Janus kinases (JAKs) are cytoplasmic tyrosine kinases that transmit signals from cytokine and interferon receptors. JAK inhibitors block this signaling, which activates signal transducer and activator of transcription (STAT) proteins. The family has four members, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). Their signaling shapes blood cell formation, immune responses and inflammation. An acquired JAK2 V617F mutation, reported in 2005, occurs in most cases of polycythemia vera and in other myeloproliferative neoplasms. The category covers inhibitors with different selectivity across the family, including ruxolitinib, baricitinib, tofacitinib citrate, momelotinib and pacritinib. Inhibitors of STAT proteins and Pim kinases are listed in the neighboring Stat and Pim categories.

Cat. No.

A33244

CAS No.

2108714-20-9

α7 nAchR-JAK2-STAT3 agonist 1

α7 nAchR-JAK2-STAT3 agonist 1 is a selective agonist targeting the α7 nicotinic acetylcholine receptor, modulating the JAK2-STAT3 signaling pathway. It demonstrates significant anti-inflammatory activity by inhibiting the expression of inducible nitric oxide synthase (iNOS), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) in murine RAW264.7 macrophages, with an IC50 of 0.32 μM for nitric oxide production. Additionally, it effectively suppresses lipopolysaccharide (LPS)-induced nitric oxide release, NF-κB activation, and related cytokine production. This compound is valuable for studying sepsis and inflammatory responses.

In stock View Details

5 mg

$395.00

10 mg

$645.00

All 5 sizes

JAK

α7 nAchR-JAK2-STAT3 agonist 1